KERX up +1.71% percent Today $KERX High is at 15.68 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 2:50 PM

KERX up +1.71% percent Today $KERX High is at 15.68 and the Low 15.41 with current volume of 303,422.

Recent News posted below.

Keryx Biopharmaceuticals KERX other info.
http://investorshangout.com/Keryx-Biopharmace...ERX-54563/

KERX Keryx Biopharmaceuticals Recent Headline News

Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST

OCN: 21.28 (+0.68), KOS: 9.50 (-0.16), KIN: 8.94 (+0.20), VSAT: 66.21 (-1.40), RFMD: 13.49 (-0.08), EBAY: 54.87 (+0.51), TQNT: 22.45 (-0.15), IDIX: 24.50 (+0.05), SEMI: 17.01 (-0.42), VRTV: 47.17 (+1.02), THRX: 13.25 (+0.02), TBPH: 17.37 (-0.11), IMOS: 21.13 (-0.76), ELOS: 9.95 (-0.34), MU: 32.28 (-0.34), AR: 52.66 (+0.15), NCQ: 0.71 (+0.02), PBF: 27.54 (+0.45), LNG: 72.19 (+0.33), ATRA: 24.43 (+1.26), KERX: 15.21 (unch), NG: 2.92 (+0.04), AOI: 1.85 (unch), FWP: 21.80 (-0.59), BYD: 11.64 (-0.42), ALDW: 17.38 (+0.25), SUNE: 16.50 (-0.43), MRK: 59.51 (+0.44), AVEO: 0.98 (+0.04), AIG: 53.98 (+0.08)

Keryx Bio presents Ferric Citrate safety data at ASN meeting
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:01AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
GlobeNewswire - Sat Nov 15, 9:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"

today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's (ASN) Kidney Week meeting in Philadelphia, PA. The results are consistent with those seen in the pivotal Phase 3 trial.
KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Fri Nov 14, 7:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.
KERX: 15.21 (unch)

'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 40.35 (+0.98), GD: 142.21 (-0.45), LMT: 185.52 (-1.08), RTN: 103.14 (-1.49), DDD: 35.60 (+1.53), NOC: 135.83 (-0.24), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), GM: 32.49 (+0.70), PG: 87.52 (-0.59), CAT: 101.95 (+0.61)

Cramer's Lightning Round - I Curse The Day I Bought General Motors (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:18AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 10. Bullish Calls: Merck (NYSE: MRK ): Cramer prefers Merck to Procter & Gamble. Intel (NASDAQ: INTC ): "INTC is underrated...
GD: 142.21 (-0.45), LMT: 185.52 (-1.08), NOC: 135.83 (-0.24), DDD: 35.60 (+1.53), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), HPQ: 37.41 (+0.49), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), SSYS: 105.06 (+0.21), GM: 32.49 (+0.70), CAT: 101.95 (+0.61), LINE: 22.24 (-0.41), PG: 87.52 (-0.59)

Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.97 (-0.01), BIIB: 305.00 (-0.43), AMAG: 35.05 (+1.05), KERX: 15.21 (unch)

Nasdaq stocks posting largest percentage increases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ESYS: 17.33 (+0.01), SWIR: 38.56 (+0.25), PERI: 5.79 (+0.12), JIVE: 6.53 (-0.30), TREE: 46.55 (-0.85), KERX: 15.21 (unch), ECYT: 6.57 (+0.15), ADEP: 8.50 (-0.09), ABTL: 10.84 (-0.48), NDLS: 23.21 (-0.27), BSFT: 26.71 (-0.79), SW.TO: 43.62 (+0.45), CALD: 15.83 (-0.23), PLNR: 7.04 (+0.35)

Keryx's (KERX) CEO Ron Bentsur on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:50AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals (KERX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST

KERX: 15.21 (unch)

Keryx Biopharma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:36AM CST
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a third-quarter loss of $35.3 million.
KERX: 15.21 (unch)

Keryx Biopharmaceuticals EPS of -$0.38
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:04AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx"

, today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013.
KERX: 15.21 (unch)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST

CYNI: 2.71 (-0.04), AAP: 145.78 (+0.97), DNOW: 28.50 (+0.16), AAON: 20.48 (-0.48), CNQ: 35.74 (-0.26), HSP: 58.36 (+0.08), CNK: 35.63 (-0.03), AMSC: 0.98 (-0.05), AES: 13.71 (+0.24), MWIV: 157.95 (+2.90), BBG: 12.95 (-1.16), HZNP: 12.52 (+0.27), KATE: 28.87 (-0.06), MITL: 10.24 (+0.12), AEE: 43.04 (+0.83), HSIC: 130.63 (+0.48), HII: 107.98 (+0.13), NAVB: 1.26 (+0.10), CECE: 14.08 (-0.46), AKRX: 37.88 (-0.33), COTY: 19.02 (-0.13), GOLD: 69.25 (+0.50), IT: 86.06 (+0.01), HNR: 2.89 (-0.10), KERX: 15.21 (unch), CECO: 5.69 (-0.20), HSC: 19.94 (+0.44), AMRC: 8.03 (-0.06), KLIC: 13.80 (-0.16), GEO: 39.30 (-0.62), AINV: 8.18 (-0.01), BCE: 47.39 (+0.52), AZN: 72.44 (-0.41), BCRX: 10.21 (+0.14), CPN: 23.45 (-0.15), BR: 45.10 (+0.03), FUR: 16.96 (+0.11), LIN: 24.00 (-0.04), LMIA: 13.88 (+0.16), CDW: 32.81 (-0.14), CVC: 18.70 (+0.16), AAWW: 41.26 (-0.35), GNRC: 41.92 (+0.05), MPEL: 25.99 (-0.54), DTV: 86.99 (-0.56), APA: 72.41 (-0.94), CRZO: 50.25 (-1.34), BKCC: 8.94 (unch), ERJ: 36.95 (+0.19), AMCX: 62.38 (+0.52), LPI: 17.15 (-0.56), HAIN: 108.29 (+0.02), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.57 (+0.53), FUN: 46.74 (-0.12), BDBD: 9.81 (+0.14)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 88.24 (+0.13), ACT: 245.62 (+1.85), HSP: 58.36 (+0.08), KERX: 15.21 (unch)

Keryx Biopharmaceuticals Up 9.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Mon Nov 03, 11:18AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on October 2nd, 2014 at $15.03. In approximately 1 month, Keryx Biopharmaceuticals has returned 9.68% as of today's recent price of $16.48.
KERX: 15.21 (unch)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.03 (-1.03), CLVS: 53.98 (-0.91), ARWR: 5.92 (-0.12), ACHN: 13.25 (-0.72), MRK: 59.51 (+0.44), RTRX: 9.45 (-0.45), RGLS: 16.80 (-0.40), EPZM: 22.68 (-0.29), AGIO: 84.96 (+0.90), RMTI: 10.55 (+0.03), ARNA: 4.53 (unch), KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, November 6, 2014 at 8:00 a.m. ET to discuss results for the third quarter of 2014 and provide an update on the business.
KERX: 15.21 (unch)

Big Board Biotech Stocks in Play This Week
ACCESSWIRE - Tue Oct 28, 1:16PM CDT
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
PACB: 7.04 (+0.24), CYTR: 2.78 (-0.01), KERX: 15.21 (unch)

Keryx Biopharmaceuticals Inc. (KERX) Stock Research Links

KERX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROKFORM Unleashes Rangefinder 18X with Bold Features

Strong Magnets and Smarter Tracking: A Golfer's Companion Forget about the agony of misplacing that pricey bit of tech you thought was secure on your golf cart. ROKFORM's new Rangefinder 18X promises to stick around with its bold tech debut. We're talking a magnet on steroids here—up to three times stronger than the competition. If your last purchase slipped on a bumpy...

Grid Hurdles Stalling Industrial Heat's Future Growth

The Grid's the New Ball and Chain Now that we're done fiddling with tech, let's talk grid. The industrial players itching to switch to electric heat have found a new villain: the grid. You'd think with resistance heating, electric boilers, electric arc furnaces, and the whole shebang ready to roll, it’d be a smooth ride. But nope, the bottleneck's the bloodstream...

MLS Org's Sue Compass to Safeguard Fair Listing Access

Real Estate Clash: MLS vs. Compass Imagine flipping on the TV to see a legal showdown brewing in the real estate world — you've got six heavy-hitter MLSs facing off against Compass, Inc. Yeah, we're talking a legal slugfest here, folks, as these MLSs rally to keep the playing field level for over 120,000 agents across the country. They're not messing around, bringing a...

Sheep Meet Solar: Maryland's Agrivoltaics Unfurled

Who would have thought sheep could be power players in Maryland's clean energy scene? But here we are, staring at a field in Cooksville where eighty sheep graze under the watchful gaze of solar panels. It’s not your everyday scene, but it’s a sign of the times when energy meets agriculture head-on. The Unlikely Marriage of Solar and Sheep What we’re looking at is a...

LEDC and Crosson Lead the Charge in Community Finance

Recognizing Game-Changers in Community Development Finance In the financial landscape, it's not always about the big tickers and glitzy IPOs. Sometimes, it's the intrepid ground-level players who make the real difference. That's exactly what happened when the Opportunity Finance Network (OFN) held its 42nd annual conference in New Orleans, honoring standouts in the realm...

College Athletics Needs a New Business Revolution

Wake Up Call for College Athletics Here's a heads-up—college sports aren't just about cheering fans and game-day jerseys anymore. It's high time universities start thinking of athletics as businesses, blending the thrill of game day with the realities of financial statements. Michael Schreiber rang this bell loud and clear on the 'Disruption Interruption' podcast,...

China's Sewing Machine Exports: Global Expansion Surge

China's Position as a Sewing Machine Powerhouse It seems like the global sewing machine market is having a bit of a renaissance, and China's sitting pretty right at the center. You see, places like Taizhou in Zhejiang Province aren’t just pushing out volume—they're slamming market demand with innovation and precision. Once known primarily as the manufacturing hub,...

Frost & Sullivan Boosts China Insight with LeadLeo

Navigating China's Complex Market Landscape You've got to understand, the stakes in China are like a high-wire act—mystifying and risky, yet bountiful if you play your cards right. Frost & Sullivan's latest maneuver into China's business intel scene is basically the lifeline for navigating this increasingly convoluted market. With China surging ahead in AI, biotech, and...

LifeWave's Bold New Path in Human Performance

Redefining the Everyday Athlete Not every day you see a wellness company talking about 'performance' in the broader human sense. Not just for the pros or those beating personal records but for anyone looking to lift the quality of their daily grind. That's the new line LifeWave's drawing in the sand with their spiffy 'Human Performance Technology.' They're looking to...

Monigle's 7 Transform Awards: Building Human Connections

Award-Winning Branding with Heart Alright, let’s dig into Monigle's world—a place where branding isn't just a static logo slapped on anything that moves but is instead about creating alive, breathing experiences that genuinely connect with people. They didn't just turn heads at the Transform Awards North America, they're the ones with jaws dropping, folks. Seven...